Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study
ConclusionsAge is a strong determinant of clinical risk as well as prasugrel prescription in ACS PCI with much lower use among older patients. Prasugrel did not have a differential treatment effect by age for MACE or bleeding.Graphic abstractFrequency of prasugrel use and age-related temporal risks of all-cause death and bleeding after ACS PCI.
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
More News: Angioplasty | Bleeding | Cardiology | Clopidogrel | Coronary Angioplasty | Heart | Heart Attack | Percutaneous Coronary Intervention | Plavix | Stroke | Study